Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.81% |
| 2 | Technology | 15.51% |
| 3 | Consumer Discretionary | 11.84% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Maravai LifeSciences
MRVI
$863M
| $47.6M | 0.07% |
3,326,948
+1,804,248
| +118% | +$28.4M |
|
352
Entergy
ETR
$50.1B
| $47.4M | 0.06% |
843,000
+256,200
| +44% | +$14M |
|
353
Newmont
NEM
$126B
| $47.3M | 0.06% |
1,002,175
-582,116
| -37% | -$26M |
|
354
ZIM Integrated Shipping Services
ZIM
$3.02B
| $47.3M | 0.06% |
2,750,942
-261,496
| -9% | -$5.82M |
|
355
Bristol-Myers Squibb
BMY
$130B
| $47.3M | 0.06% |
+657,200
| New | +$49.6M |
|
356
Builders FirstSource
BLDR
$7.77B
| $47.1M | 0.06% |
725,741
-45,500
| -6% | -$2.84M |
|
357
Paylocity
PCTY
$7.62B
| $47M | 0.06% |
242,200
+117,041
| +94% | +$25.1M |
|
|
EA
358
DELISTED
Electronic Arts
EA
| $47M | 0.06% |
384,400
-17,900
| -4% | -$2.25M |
|
359
ResMed
RMD
$32.4B
| $46.8M | 0.06% |
224,896
+178,340
| +383% | +$39.2M |
|
360
Super Micro Computer
SMCI
$23.1B
| $46.7M | 0.06% |
5,686,400
+1,952,250
| +52% | +$14.9M |
|
361
Sturm, Ruger & Co
RGR
$602M
| $46.5M | 0.06% |
917,876
-68,800
| -7% | -$3.74M |
|
362
Calix
CALX
$2.48B
| $46.2M | 0.06% |
675,435
-122,265
| -15% | -$8.22M |
|
363
Hasbro
HAS
$13.5B
| $45.9M | 0.06% |
+751,900
| New | +$47M |
|
364
Exelon
EXC
$46.3B
| $45.8M | 0.06% |
1,059,424
-435,000
| -29% | -$17.2M |
|
365
Graphic Packaging
GPK
$3.48B
| $45.5M | 0.06% |
2,046,218
+1,759,500
| +614% | +$38.7M |
|
366
Celanese
CE
$4.79B
| $45.2M | 0.06% |
441,800
-266,409
| -38% | -$26.4M |
|
367
Toll Brothers
TOL
$13.9B
| $45.2M | 0.06% |
+904,700
| New | +$41.6M |
|
368
Dentsply Sirona
XRAY
$2.24B
| $45.1M | 0.06% |
1,416,458
+199,400
| +16% | +$6.01M |
|
369
Post Holdings
POST
$3.57B
| $45M | 0.06% |
498,700
+248,601
| +99% | +$22.2M |
|
370
Supernus Pharmaceuticals
SUPN
$2.71B
| $45M | 0.06% |
1,260,522
-19,700
| -2% | -$685K |
|
|
SLCA
371
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $44.9M | 0.06% |
3,593,508
-494,300
| -12% | -$6.33M |
|
372
UFP Technologies
UFPT
$2.45B
| $44.8M | 0.06% |
379,873
-18,200
| -5% | -$1.94M |
|
373
Takeda Pharmaceutical
TAK
$55.6B
| $44.7M | 0.06% |
2,864,400
+15,300
| +0.5% | +$214K |
|
374
Ionis Pharmaceuticals
IONS
$9.4B
| $44.5M | 0.06% |
1,178,814
+311,100
| +36% | +$13.1M |
|
375
SSR Mining
SSRM
$6.65B
| $44.3M | 0.06% |
2,827,543
-405,500
| -13% | -$5.94M |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.